①Cell：A pan-cancer single-cell panorama of human natural killer cells

人類自然殺傷(NK)細胞在腫瘤微環境中的表型和功能多樣性

DOI: 10.1016/j.cell.2023.07.034

②Cancer Cell：CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration

來自肺腺癌(ADC)中CD44+肺癌干細胞(CSCs)的血管周細胞通過g蛋白偶聯受體124 (GPR124)增強的跨內皮遷移(TEM)導致腦轉移

DOI: 10.1016/j.ccell.2023.07.012

③Cancer Cell：Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

綜述：推進癌癥免疫治療的新輔助免疫檢查點阻斷(ICB)策略

DOI: 10.1016/j.ccell.2023.07.011

④Cell Genomics：Polygenic regression uncovers trait-relevant cellular contexts through pathway activation transformation of single-cell RNA sequencing data

多基因回歸通過單細胞RNA測序(scRNA-seq)數據的通路激活轉化揭示與性狀相關的細胞背景

DOI: 10.1016/j.xgen.2023.100383

⑤iScience：A randomized clinical trial of Bermekimab treatment for clinical improvement of systemic sclerosis

臨床試驗：全人源化IL-1α阻斷單克隆抗體貝邁奇單抗（Bermekimab）用于系統性硬化癥（SSc）的一項雙盲、隨機、安慰劑對照研究

DOI: 10.1016/j.isci.2023.107670

⑥iScience：Integrative analysis of single-cell RNA-seq and ATAC-seq reveals heterogeneity of induced pluripotent stem cell derived hepatic organoids

單細胞RNA測序（scRNA-seq）和單細胞染色質開放性測序技術（scATAC-seq）的綜合分析揭示了誘導多能干細胞衍生的肝類器官的異質性

DOI: 10.1016/j.isci.2023.107675

⑦選擇性小分子口服脾酪氨酸激酶（Syk）抑制劑索樂匹尼布(Sovleplenib)用于成人原發免疫性血小板減少癥（ITP）的中國關鍵性III期研究達到主要終點以及所有次要終點

⑧GLP-1R/GIPR雙靶點激動劑替爾泊肽（Tirzepatide）減重適應癥的上市申請獲得NMPA受理

⑨GLP-1/GCG雙重激動劑BI456906（Survodutide）將啟動用于超重或肥胖的三項注冊Ⅲ期臨床

⑩第一類蛋白激酶C（PKC）抑制劑?Darovasertib (IDE196)單藥用于原發性葡萄膜黑色素瘤（UM）患者的新輔助或輔助治療的Ⅱ期臨床首例患者給藥

科學探索的世界充滿挑戰，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！